LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
LLY
747.85
-0.07%↓
UNH
590.82
-1.04%↓
JNJ
155.2
-0.15%↓
NVO
105.18
+2.52%↑
ABBV
177.14
+3.17%↑
24h
Current
Min
65.56
Max
65.7
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +33.58 upside |
By Trading Central
Confidence
Strong Bullish Evidence
64.27 / 65.98 Support & Resistance
Past performance is not a reliable indicator of future results.
١٢ نوفمبر ٢٠٢٤، ٠٧:٥٥ م UTC
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
DJ
Read
١٢ نوفمبر ٢٠٢٤، ١١:٠٢ ص UTC
AstraZeneca Raises Outlook, Plans U.S. Investment -- Update
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٣٧ ص UTC
AstraZeneca Raises Outlook on Earnings, Sales Beat
DJ
Read
١٠ سبتمبر ٢٠٢٤، ٠٩:٢٩ ص UTC
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
DJ
Read
١٨ نوفمبر ٢٠٢٤، ١٠:٣٣ ص UTC
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
DJ
Read
١٥ نوفمبر ٢٠٢٤، ٠١:٠٨ م UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Read
١٥ نوفمبر ٢٠٢٤، ١٠:٢٩ ص UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٣:٣٠ م UTC
AstraZeneca Expands U.S. Investment Plan -- 2nd Update
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠١:٣٩ م UTC
AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk
DJ
Read
١٢ نوفمبر ٢٠٢٤، ١٠:٤٩ ص UTC
AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٩:٥٢ ص UTC
AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC
AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC
AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC
AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC
AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٢ ص UTC
AstraZeneca Raises 2024 View
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠١ ص UTC
Analysts Saw AstraZeneca 3Q Sales at $13.1B
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠١ ص UTC
Analysts Saw AstraZeneca 3Q Core EPS at $2.04
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC
AstraZeneca PLC 3Q EPS 91c
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC
AstraZeneca PLC 3Q Net Pft $1.43B
DJ
Read
١٢ نوفمبر ٢٠٢٤، ٠٧:٠٠ ص UTC
AstraZeneca PLC 3Q Oper Pft $2.11B
DJ
Read
٧ نوفمبر ٢٠٢٤، ٠٨:٠٣ ص UTC
China Has Detained a Senior AstraZeneca Executive -- Update
DJ
Read
٦ نوفمبر ٢٠٢٤، ٠٦:٥٥ م UTC
China Has Detained Senior AstraZeneca Executive -- WSJ
DJ
Read
١ نوفمبر ٢٠٢٤، ٠٣:٠٠ ص UTC
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ
DJ
Read
٣١ أكتوبر ٢٠٢٤، ٠٧:٤٨ م UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Read
٣١ أكتوبر ٢٠٢٤، ٠٢:٤٣ م UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ
DJ
Read
١٢ سبتمبر ٢٠٢٤، ٠٥:٠١ م UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
DJ
Read
١٢ سبتمبر ٢٠٢٤، ١١:٠٠ ص UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
DJ
Read
١٠ سبتمبر ٢٠٢٤، ٠١:٠٨ م UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
DJ
Read
٩ سبتمبر ٢٠٢٤، ٠٧:٥٦ ص UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 87.67 USD 33.58%
High 88 USD
Low 87 USD
Based on 6 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
5
Buy
1
Hold
0
Sell
Based on 6 analysts giving stock ratings to AstraZeneca PLC ADR - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Intermediate Term
Strong Bearish Evidence
All events are bearish.
Long Term
Bearish Evidence
All events are bearish.
$